It is better to be in a clinical trial than not: lessons learnt from clinical neurology—the management of acute multiple sclerosis relapses
QJM: An International Journal of Medicine, 05/04/2012McNicholas M et al.
The effect observed is likely secondary to trial participation; both groups had similar baseline features, and were treated in the same way. Likely mechanisms for the differences are protocol, care and Hawthorne effects. The findings support the incorporation of structured randomized controlled trial (RCT)–style practice into routine clinical management, in order to deliver a more patient–centred care in the treatment of multiple sclerosis relapses. This may have implications for other chronic neurological diseases.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.